Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.

Tiberg F, Roberts J, Cervin C, Johnsson M, Sarp S, Tripathi AP, Linden M

British journal of clinical pharmacology6 Aug 2015Cited by 51 (Europe PMC)

PMID26076191PMCIDPMC4574831DOI10.1111/bcp.12698PepBankPUB-26076191

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialPharmacokinetics
In healthy volunteers, octreotide plasma concentrations indicated a trend toward dose dependence.
In plain wordsIn healthy volunteers, octreotide blood concentrations showed a trend toward dose dependence.
Peptide
Octreotide
Outcome
Direction not reportedDose dependence of plasma concentration
Study
n: not reported in source
Comparator
Other randomized octreotide doses
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Depot A 10, 20 or 30 mg, B 30 mg, or C 10, 20 or 30 mg monthly · subcutaneous · three monthly injectionsAs given in this study (human).
Source sentences
Summary
A trend of octreotide dose dependence was also indicated from the plasma concentrations and suppression of IGF-1.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
Summary · context
After a single dose of octreotide immediate release (IR) 200 µg, subjects were randomized to one of eight groups to receive three monthly injections of octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg or long acting octreotide (octreotide LAR) 30 mg.
Title · context
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.
Report a problemFND-2607619105
02HumanRandomized controlled trialEfficacy outcome
In healthy volunteers, octreotide IGF-1 suppression indicated a trend toward dose dependence.
In plain wordsIn healthy volunteers, IGF-1 suppression showed a trend toward octreotide dose dependence.
Peptide
Octreotide
Outcome
Direction not reportedDose dependence of IGF-1 suppression
Study
n: not reported in source
Comparator
Other randomized octreotide doses
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Depot A 10, 20 or 30 mg, B 30 mg, or C 10, 20 or 30 mg monthly · subcutaneous · three monthly injectionsAs given in this study (human).
Source sentences
Summary
A trend of octreotide dose dependence was also indicated from the plasma concentrations and suppression of IGF-1.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
Summary · context
After a single dose of octreotide immediate release (IR) 200 µg, subjects were randomized to one of eight groups to receive three monthly injections of octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg or long acting octreotide (octreotide LAR) 30 mg.
Title · context
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.
Report a problemFND-2607619106
03HumanNon-randomized trialPharmacokinetics
In healthy volunteers, all octreotide depot variants released octreotide rapidly and sustained release for up to 4 weeks.
In plain wordsIn healthy volunteers, all octreotide depot variants released the drug rapidly for up to 4 weeks.
Peptide
Octreotide
Outcome
Not applicableRelease onset and persistence
Study
n: not reported in source
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Depot A 10, 20 or 30 mg, B 30 mg, or C 10, 20 or 30 mg monthly · subcutaneousAs given in this study (human).
Measurements
Release persistence
≤ 4 weeks
all depot variants
Source sentences
Summary
For all depot variants, onset of octreotide release was rapid and sustained for up to 4 weeks.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
Summary · context
After a single dose of octreotide immediate release (IR) 200 µg, subjects were randomized to one of eight groups to receive three monthly injections of octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg or long acting octreotide (octreotide LAR) 30 mg.
Title · context
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.
Report a problemFND-2607619101
04HumanNon-randomized trialSafety outcome
In healthy volunteers, all octreotide depot treatments were well tolerated.
In plain wordsIn healthy volunteers, all octreotide depot treatments were well tolerated.
Peptide
Octreotide
Outcome
Not applicableTolerability
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Depot A 10, 20 or 30 mg, B 30 mg, or C 10, 20 or 30 mg monthly · subcutaneous · three monthly injectionsAs given in this study (human).
Source sentences
Summary
All depot treatments were well tolerated.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
Summary · context
After a single dose of octreotide immediate release (IR) 200 µg, subjects were randomized to one of eight groups to receive three monthly injections of octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg or long acting octreotide (octreotide LAR) 30 mg.
Title · context
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.
Report a problemFND-2607619108
05HumanNon-randomized trialSafety outcome
In healthy volunteers receiving octreotide depot treatments, gastrointestinal events were the most frequent adverse events.
In plain wordsIn healthy volunteers receiving octreotide depot treatments, gut-related events were the most frequent adverse events.
Peptide
Octreotide
Outcome
Direction not reportedGastrointestinal adverse events
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
Depot A 10, 20 or 30 mg, B 30 mg, or C 10, 20 or 30 mg monthly · subcutaneous · three monthly injectionsAs given in this study (human).
Source sentences
Summary
The most frequent adverse events were gastrointestinal related.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
Summary · context
After a single dose of octreotide immediate release (IR) 200 µg, subjects were randomized to one of eight groups to receive three monthly injections of octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg or long acting octreotide (octreotide LAR) 30 mg.
Title · context
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers.
Report a problemFND-2607619109

Studies that did not test the peptide alone4

In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Octreotide.

06HumanNot a test of Octreotide aloneRandomized controlled trialPharmacokinetics
In healthy volunteers, octreotide depot variants had approximately four- to five-fold greater bioavailability than octreotide LAR.
In plain wordsIn healthy volunteers, octreotide depot variants had greater bioavailability than octreotide LAR.
Peptide
Octreotide
Outcome
IncreaseBioavailability versus LAR
Study
n: not reported in source
Comparator
Octreotide LAR
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Relative bioavailability vs octreotide LAR
3.97 to 5.27 ng ml(-1) h
depot variants vs octreotide LAR
90% CI (lowest ratio)
3.35 to 4.71 ng ml(-1) h
depot variants vs octreotide LAR
90% CI (highest ratio)
4.43 to 6.27 ng ml(-1) h
depot variants vs octreotide LAR
Source sentences
Summary
and, vs. octreotide LAR, was approximately four- to five-fold greater: 3.97 (90% CI 3.35, 4.71) to 5.27 ng ml(-1) h (90% CI 4.43, 6.27).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Octreotide.
Report a problemFND-2607619103
07HumanNot a test of Octreotide aloneRandomized controlled trialEfficacy outcome
In healthy volunteers, octreotide depot variants reduced IGF-1 more rapidly initially than octreotide LAR.
In plain wordsIn healthy volunteers, octreotide depot variants reduced IGF-1 more rapidly than octreotide LAR.
Peptide
Octreotide
Outcome
DecreaseInitial IGF-1 reduction
Study
n: not reported in source
Comparator
Octreotide LAR
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
All depot variants showed relatively rapid initial reductions of insulin-like growth factor 1 (IGF-1) compared with octreotide LAR.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Octreotide.
Report a problemFND-2607619104
08HumanNot a test of Octreotide aloneRandomized controlled trialEfficacy outcome
In healthy volunteers, octreotide depot B and C showed the highest maximum IGF-1 inhibition at steady state.
In plain wordsIn healthy volunteers, octreotide depot B and C showed the highest maximum IGF-1 suppression.
Peptide
Octreotide
Outcome
IncreaseMaximum steady-state IGF-1 inhibition
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Maximum inhibition of IGF-1 at steady-state was highest for depot B and C.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Octreotide.
Report a problemFND-2607619107
09HumanNot a test of Octreotide aloneNon-randomized trialPharmacokinetics
In healthy volunteers, octreotide depot variants had relative bioavailability of 0.68 to 0.91 versus octreotide IR.
In plain wordsIn healthy volunteers, octreotide depot variants had 0.68 to 0.91 of the bioavailability of octreotide IR.
Peptide
Octreotide
Outcome
DecreaseBioavailability versus immediate release
Study
n: not reported in source
Comparator
Octreotide IR
Outcome group
Pharmacokinetics · Pharmacology
Measurements
Relative bioavailability vs octreotide IR
0.68 to 0.91
depot variants vs octreotide IR
90% CI (lowest ratio)
0.61 to 0.76
depot variants vs octreotide IR
90% CI (highest ratio)
0.81 to 1.02
depot variants vs octreotide IR
Source sentences
Summary
The relative octreotide bioavailability of depot variants vs. octreotide IR ranged from 0.68 (90% confidence interval [CI] 0.61, 0.76) to 0.91 (90% CI 0.81, 1.02)
1 context sentence(design, population, supporting numbers)
Summary · context
This was a phase I, randomized, open label study.
In this study, Octreotide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Octreotide.
Report a problemFND-2607619102

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.